All
Next Steps for Evaluating Balstilimab Plus Botensilimab in MSS mCRC
Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in microsatellite stable metastatic colorectal cancer without liver metastases.
Exploring Fixed-Duration Ibrutinib and Venetoclax in CLL Treatment
Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what findings from the trial have been particularly noteworthy.
Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment
Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.
FDA Clears Phase 1 Trial of MRANK-106 in Advanced Solid Tumors
The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors.
Guidelines for Mesothelioma Now Offer More Treatment Options
Hedy Lee Kindler, MD, explains the new treatment updates for patients with mesothelioma.
BREAKWATER Trial Highlights ORR Boost in BRAF V600E mCRC
For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer.
FDA Grants Rhenium Obisbemeda Orphan Drug Status for LM in Lung Cancer
The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.
Durvalumab Plus Chemotherapy Boosts EFS in Gastric/GEJ Cancer
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.
AI Writes Appeal Letters for Denied Claims...and Wins
Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare administrative waste.
Immunotherapy Advances in Small Cell Lung Cancer Treatment
Joe Leach, MD, discusses some of the latest developments in incorporating immunotherapy into small cell lung cancer treatment regimens.
Cutting Delays in Cancer Care With Centralized Prior Authorizations
Andrea Ledford, PharmD, MBA, BCOP, BCSCP, FASHP, FHOPA, discussed a comprehensive pharmacy program presented at the 2025 ACCC Annual Meeting & Cancer Center Business Summit.
Moving Beyond BCG in Bladder Cancer
Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies is relevant.
FDA OKs Trial of Novel CAR T-Cell Therapy in T-ALL/LBL
The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute lymphoblastic leukemia and lymphoma.
Evaluating Survival, Long-Term Use of Nirogacestat in Desmoid Tumors
Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.
42nd Annual Miami Breast Cancer Conference: The Show and After Show
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
SECuRE Trial Highlights Safety, Efficacy of 67Cu-SAR-bisPSMA in mCRPC
The dose-escalation phase of the SECuRE trial in prostate cancer has completed and demonstrated promising safety and efficacy data.
ASCO Updates Guidelines for Malignant Pleural Mesothelioma Treatment
Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve pathologic classification for personalized care.
FDA Grants Bexmarilimab Orphan Drug Designation for MDS
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.
First Patient Dosed in Phase 1/2 Trial of HLD-0915 for mCRPC
A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to 80 patients.
NIH Funding Fuels Advances in Cancer Treatment and Therapies
Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.
Two Denosumab Biosimilars Pocket FDA Approval in Multiple Indications
Two denosumab biosimilars have gained FDA approvals across multiple indications.
T-DXd Improves Survival in Second-Line HER2+ GI Cancer
Trastuzumab deruxtecan demonstrated a significant survival benefit in HER2-positive metastatic gastric cancer in the phase 3 DESTINY-Gastric04 trial.
FDA Approves Frontline Tislelizumab Plus Chemotherapy in Advanced ESCC
Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 expression of 1 or higher.
FDA Approvals & Designations in Oncology: February 2025 Highlights
Here is a look back on all the FDA happenings from the month of February 2025.
HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies
Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.
Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
How AI is Revolutionizing MDS Diagnosis
Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.
Rusfertide Shows Superior Efficacy in Phase 3 Polycythemia Vera Trial
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.
First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial
A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.
